Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: This study does not intervene in this process..
- Who it may be relevant to
- Registry conditions: Brain (Nervous System) Cancers, Glioma, Brain Tumor. Basic parameters: 18 years — 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Primary central nervous system (CNS) tumors, the vast majority (\>90%) occurring in the brain and the remainder occurring in the meninges, spinal cord, and cranial nerves, showing an annual incidence of about 6-8 people per 100,000 population but its effects on health-care systems is out of proportion with incidence due to the substantial high rates of morbidity and mortality. Among which, glioma disease is the most common primary malignant CNS tumor, while the glioblastoma that showed the highest degree of malignancy and the worst prognosis accounts for 70-75%. The construction goal of this project is to construct a multivariate retrospective CNS tumor database (over 50,000 cases, including 10,000 glioma) integrating clinical information, preoperative magnetic resonance imaging examination and molecular pathological results, and a prospective glioma database (3,000 cases) integrating advanced magnetic resonance sequences and postoperative follow-up. It aims to form a standardized database integrating magnetic resonance imaging, pathological results, and clinical-prognostic information. Based on the construction of the above standardized database, the specifications for the acquisition of cranial magnetic resonance images, the image segmentation, tumor classification and labeling process, and the expert consensus on database construction and use management of CNS tumors were established. We aim to form a multimodal, large-capacity, high-quality, and rich medical imaging database that conforms to the characteristics of Chinese groups and clinical diagnosis and treatment norms. On this basis, the data are dynamically updated, in-depth mining, and the classification and grading standards of CNS tumor diseases, prognosis judgment criteria and treatment efficacy evaluation system are formulated, and providing comprehensive resources of retrospective data and prospective cohorts for large-scale reasearches, such as classification or treatment intervention predictions.
Interventions
- Diagnostic test This study does not intervene in this process.
This study does not intervene in this process.
Primary outcome measures
- Establish standardized clinical-MRI-molecular markers database for CNS tumors [Time frame: 2022.06-2023.12]
- Establish prospective brain tumor cohort with multiomics information [Time frame: 2022.06.01-2030.12.31]
Secondary outcome measures (1)
- Accurately predicting the molecular and survival of glioma patients based on a deep learning model [Time frame: 2022.01-2024.12]
Eligibility criteria
Inclusion criteria
- (1) a clear diagnosis of glioma based on pathological results;
- (2) The MRI sequence is complete and there are no obvious artifacts in the image;
- (3) The patient signs an informed consent form
Exclusion criteria
- (1) Suffering from other neurological diseases;
- (2) Prior to enrollment, surgery or biopsy, or a history of radiation therapy or chemotherapy;
- (3) Unable to complete clinical scoring and related laboratory tests, unable to complete follow-up;
- (4) Unable to tolerate MRI examination; Poor image quality, such as motion artifacts.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Beijing Tiantan Hospital — Beijing
Identifiers
NCT: NCT05859659 · KY2022-078-04